2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

Sickle cell disease

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148788
    Osivelotor

    GBT-601; GBT-021601

    		 Others Others
    Osivelotor is an allosteric modulator of haemoglobin S (HbS) . Osivelotor can be used in the study of sickle cell disease (SCD).
    Osivelotor
  • HY-18681
    Voxelotor
    5+ Cited Publications

    GBT 440

    		 Others Cardiovascular Disease
    Voxelotor (GBT 440) is a potent inhibitor of haemoglobin S (HbS) polymerization. Voxelotor has the potential for sickle cell disease (SCD) treatment .
    Voxelotor
  • HY-109193
    Tovinontrine

    IMR-687

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Tovinontrine (IMR-687) is a highly potent and selective phosphodiesterase-9 (PDE9) inhibitor specifically for the treatment of sickle cell disease. IC50s are 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively .
    Tovinontrine
  • HY-P9987
    Crizanlizumab

    		P-selectin Cardiovascular Disease
    Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease .
    Crizanlizumab
  • HY-139293
    PF-07059013

    		Others Cardiovascular Disease
    PF-07059013 is an orally active and potent noncovalent modulator of sickled hemoglobin (HbS). PF-07059013 specifically binds to Hb with nanomolar affinity and displays strong partitioning into red blood cells (RBCs). PF-07059013 can be used for sickle cell disease (SCD) research .
    PF-07059013
  • HY-106509
    Velaresol

    BW 12C; 12C79; BW 12C79

    		 Others Others
    Velaresol (BW 12C) is a potent left-shifting anti-sickling compound in vitro . Sickle cell disease is an inherited disorder of the hemoglobin molecule. When hemoglobin molecules are exposed to a variety of environments, the red blood cell hemoglobin polymerizes, twists, and morphs into a sickle shape.
    Velaresol
  • HY-139573
    Etavopivat

    FT-4202

    		 Pyruvate Kinase Cardiovascular Disease
    Etavopivat is a potent, selective, and orally active erythrocyte pyruvate kinase (PKR) activator. Etavopivat has potent antisickling effects that can be used in studies of sickle cell disease and other haemoglobinopathies .
    Etavopivat
  • HY-139573A
    (Rac)-Etavopivat

    (Rac)-FT-4202

    		 Pyruvate Kinase Cardiovascular Disease
    (Rac)-Etavopivat ((Rac)-FT-4202) is an isomer of Etavopivat (HY-139573). Etavopivat is an orally active erythrocyte pyruvate kinase-R (PKR) activator that can be used in studies of sickle cell disease and other haemoglobinopathies .
    (Rac)-Etavopivat
  • HY-139400A
    Pociredir hydrochloride

    FTX-6058 hydrochloride

    		 Histone Methyltransferase Cardiovascular Disease
    Pociredir (FTX-6058) hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir hydrochloride can induce HbF protein expression in cell and murine models. Pociredir hydrochloride can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .
    Pociredir hydrochloride
  • HY-139400
    Pociredir

    FTX-6058

    		 Histone Methyltransferase Cardiovascular Disease
    Pociredir (FTX-6058) is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir can induce HbF protein expression in cell and murine models. Pociredir can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .
    Pociredir
  • HY-152775A
    RK-0133114

    		Histone Methyltransferase Metabolic Disease
    RK-0133114 is a G9a inhibitor and a R-enantiomer of RK-701 (HY-152775). RK-0133114 inhibits G9a with an IC50 value of 3.7 μM. RK-0133114 can be used for the research of sickle cell disease (SCD) .
    RK-0133114
  • HY-153182
    GBT1118

    		Others Cardiovascular Disease
    GBT1118 is a potent and orally active allosteric modifier of hemoglobin oxygen affinity. GBT1118 increases tolerance to severe hypoxia .
    GBT1118
  • HY-150510
    MS8511

    		Histone Methyltransferase Neurological Disease Cancer
    MS8511 is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC50 values of 100 nM (G9a) and 140 nM (GLP), and Kd values of 44 nM (G9a) and 46 nM (GLP). MS8511 reduces the cellular H3K9me2 level and enhances antiproliferation activity. MS8511 can be used for the research of several types of cancers including brain, breast, ovarian, lung, bladder, melanoma, colorectal cancer, and other disease such as Alzheimer’s disease (AD), sickle cell disease, Prader−Willi syndrome (PWS) .
    MS8511
  • HY-110130
    RN-1 dihydrochloride

    		Histone Demethylase Cardiovascular Disease Cancer
    RN-1 dihydrochloride is a potent, brain-penetrant, irreversible and selective lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 70 nM. RN-1 dihydrochloride exhibits selectivity for LSD1 over MAO-A and MAO-B with IC50 values of 0.51 μM and 2.785 μM respectively .
    RN-1 dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: